以丹参酮IIA为代表的丹参酮类化合物是中药丹参的主要活性成分之一，在临床上已广泛用于心血管系统疾病的治疗，近年来，其抗炎和抗肿瘤活性也逐渐得到重视，诸多的药理药效活性使其具有广阔的应用前景，同时也对丹参资源提出了挑战。目前丹参酮主要是从丹参（Salvia miltiorrhiza Bge.）中提取，含量相对较低，另外不完全提取也在一定程度上对丹参资源造成了浪费。通过丹参酮生物合成途径的解析，利用合成生物学方法在微生物细胞中重构丹参酮的生成模块，可以实现异源高效合成，为中药制剂生产提供大量原材料。但是目前丹参酮的生物合成途径尚未完全解析，本项目拟在前期工作的基础上，通过利用多重比较转录组分析结合共表达分析、体外酶促分析、体内功能研究技术以期获得催化丹参酮核心结构五元呋喃环生物合成的关键酶基因，并利用模块化途径工程技术和系统整合优化手段构建高产丹参酮IIA的酵母基因工程菌。

Tanshinone IIA and other tanshinones are the principal active component of Danshen. It has been widely used in cardiovascular diseases. In addition to the well-studied cardiovascular activity, tanshinones has been investigated more recently for their anti-inflammation and anti-cancer activities, which supported its great prospects in pharmaceutical application, but also challenged the resources of Danshen. Tanshinones are extracted from Salvia miltiorrhiza Bge.. But the content of tanshinones in Danshen is relatively low. Moreover, insufficient extraction might be a waste for resources. Synthetic biology based on biopathway characterization which reconstructed the biopathway into the bacteria provides an alternative for production of tanshinones. However, the biopathway of tanshinones remains uncharacterized. In this study, the multiple comparative transcriptome analysis, co-expression analysis, in vitro enzyme reaction and in vivo functional characterization analysis will be used to characterize the key enzyme involving in biosynthesis of the furan ring of tanshinones. At last, the modular pathway strategy and systematic optimization will be used to reconstruct the biopathway in the metabolically engineering yeast to produce tanshinone IIA.